Apertura Gene Therapy is a biotechnology company founded in 2021 with the mission to advance gene therapies for severe, unmet medical needs. Based in New York City and supported by Deerfield Management Company, the company's work is based on platform technologies developed at the Broad Institute of Harvard and MIT. Apertura specializes in engineering next-generation AAV (adeno-associated virus) capsids and payloads to overcome major limitations in gene therapy delivery and expression, with a particular focus on creating non-invasive solutions to target the central nervous system.